Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has appointed Dr. Nancy T. Chang to its Board of Directors. Dr. Chang, former CEO of Tanox Inc., joins concurrent with her investment through Goose Capital.
Dr. Chang brings significant expertise, having led the development of several successful drugs including XOLAIR® for severe asthma, TROGARZO® for HIV, and EBGLYSS® for dermatitis. These drugs have collectively generated over $5 billion in sales. Notably, under her leadership, Tanox was acquired by Genentech/Roche for $919 million.
Immix Biopharma (NASDAQ:IMMX), azienda biofarmaceutica in fase clinica, ha nominato Dr.ssa Nancy T. Chang nel proprio Consiglio di Amministrazione. La nomina coincide con il suo investimento tramite Goose Capital.
La Dr.ssa Chang apporta una solida esperienza avendo guidato lo sviluppo di diversi farmaci di successo, tra cui XOLAIR® per l'asma grave, TROGARZO® per l'HIV e EBGLYSS® per la dermatite. Questi prodotti hanno generato complessivamente oltre $5 miliardi di vendite. Sotto la sua guida, Tanox è stata acquisita da Genentech/Roche per $919 milioni.
Immix Biopharma (NASDAQ:IMMX), una compañía biofarmacéutica en fase clínica, ha nombrado a la Dra. Nancy T. Chang en su Junta Directiva. El nombramiento se produce junto con su inversión a través de Goose Capital.
La Dra. Chang aporta una amplia experiencia, habiendo liderado el desarrollo de varios medicamentos exitosos, incluidos XOLAIR® para el asma grave, TROGARZO® para el VIH y EBGLYSS® para la dermatitis. Estos fármacos han generado en conjunto más de $5 mil millones en ventas. Cabe destacar que, bajo su liderazgo, Tanox fue adquirida por Genentech/Roche por $919 millones.
Immix Biopharma (NASDAQ:IMMX), 임상 단계의 바이오제약회사로서 Dr. Nancy T. Chang을 이사회 이사로 선임했습니다. 이번 선임은 그녀가 Goose Capital을 통해 투자한 것과 동시에 이루어졌습니다.
Dr. Chang은 중증 천식을 위한 XOLAIR®, HIV 치료제 TROGARZO®, 피부염 치료제 EBGLYSS® 등 여러 성공적인 약물 개발을 주도한 풍부한 경험을 보유하고 있습니다. 이들 약물은 총 $50억 이상의 매출을 기록했습니다. 또한 그녀의 리더십 하에 Tanox는 Genentech/Roche에 $9.19억에 인수되었습니다.
Immix Biopharma (NASDAQ:IMMX), société biopharmaceutique en phase clinique, a nommé Dr Nancy T. Chang au sein de son conseil d'administration. Cette nomination intervient en parallèle de son investissement via Goose Capital.
Dr Chang apporte une expertise significative, ayant piloté le développement de plusieurs médicaments à succès, notamment XOLAIR® pour l'asthme sévère, TROGARZO® pour le VIH et EBGLYSS® pour la dermatite. Ces médicaments ont généré au total plus de 5 milliards de dollars de ventes. Sous sa direction, Tanox a été acquise par Genentech/Roche pour 919 millions de dollars.
Immix Biopharma (NASDAQ:IMMX), ein biopharmazeutisches Unternehmen in klinischer Phase, hat Dr. Nancy T. Chang in seinen Vorstand berufen. Die Berufung erfolgt zugleich mit ihrem Investment über Goose Capital.
Dr. Chang bringt umfassende Expertise mit: Sie leitete die Entwicklung mehrerer erfolgreicher Medikamente, darunter XOLAIR® bei schwerem Asthma, TROGARZO® bei HIV und EBGLYSS® bei Dermatitis. Diese Präparate haben zusammen über $5 Milliarden Umsatz erzielt. Unter ihrer Führung wurde Tanox von Genentech/Roche für $919 Millionen übernommen.
- Appointment of highly experienced biotech leader with proven track record of drug development
- New director has history of successful drug commercialization exceeding $5 billion in sales
- Strategic addition of leader who achieved $919 million exit through Tanox acquisition
- None.
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding
Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her investment as founding member of Goose Capital.
At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far.
Tanox, Inc. was acquired by Genentech/Roche for
EBGLYSS® is commercialized by Eli Lilly and Co.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
Who is Nancy T. Chang and why did IMMX appoint her to the Board?
What are the major achievements of Nancy T. Chang in biotechnology?
What is Immix Biopharma (IMMX) currently developing?
What is Nancy T. Chang's role at Goose Capital?
